Abstract
Twelve premenopausal patients with advanced breast cancer were randomised to receive 3.75 or 7.5 mg of a slow release formulation of the luteinising hormone releasing hormone agonist leuprorelin once every 4 weeks. All patients were oestrogen receptor positive or unknown. Serum levels of gonadotrophins and oestrogens were suppressed markedly by both doses. All oestrogen values during treatment were within the postmenopausal range except for a single oestradiol level (274 pmol l-1) in one patient on the lower dose. There was no other indication that this lower dose was less effective as an oestrogen suppressant. There were two objective responders to the 3.75 mg dose and three to the 7.5 mg dose. Toxicity was confined almost entirely to hot flushes which occurred in 11/12 patients. We conclude that the slow release formulation of leuprorelin is effective in breast cancer treatment and that there is no major detriment to the use of the 3.75 rather than 7.5 mg dose.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Crighton I. L., Dowsett M., Lal A., Man A., Smith I. E. Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects. Br J Cancer. 1989 Oct;60(4):644–648. doi: 10.1038/bjc.1989.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dowsett M., Cantwell B., Lal A., Jeffcoate S. L., Harris A. L. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Endocrinol Metab. 1988 Apr;66(4):672–677. doi: 10.1210/jcem-66-4-672. [DOI] [PubMed] [Google Scholar]
- Dowsett M., Goss P. E., Powles T. J., Hutchinson G., Brodie A. M., Jeffcoate S. L., Coombes R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987 Apr 1;47(7):1957–1961. [PubMed] [Google Scholar]
- Ferguson K. M., Hayes M., Jeffcoate S. L. A standardised multicentre procedure for plasma gonadotrophin radioimmunoassay. Ann Clin Biochem. 1982 Sep;19(Pt 5):358–361. doi: 10.1177/000456328201900507. [DOI] [PubMed] [Google Scholar]
- Harris A. L., Dowsett M., Jeffcoate S. L., Smith I. E. Aminoglutethimide dose and hormone suppression in advanced breast cancer. Eur J Cancer Clin Oncol. 1983 Apr;19(4):493–498. doi: 10.1016/0277-5379(83)90112-8. [DOI] [PubMed] [Google Scholar]
- Harvey H. A., Lipton A., Max D. T., Pearlman H. G., Diaz-Perches R., de la Garza J. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J Clin Oncol. 1985 Aug;3(8):1068–1072. doi: 10.1200/JCO.1985.3.8.1068. [DOI] [PubMed] [Google Scholar]
- Jackson I. M., Matthews M. J., Diver J. M. LHRH analogues in the treatment of cancer. Cancer Treat Rev. 1989 Sep;16(3):161–175. doi: 10.1016/0305-7372(89)90008-x. [DOI] [PubMed] [Google Scholar]
- Sandow J. Clinical applications of LHRH and its analogues. Clin Endocrinol (Oxf) 1983 Jun;18(6):571–592. doi: 10.1111/j.1365-2265.1983.tb00595.x. [DOI] [PubMed] [Google Scholar]
- Santen R. J., Manni A., Harvey H. Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma. Breast Cancer Res Treat. 1986;7(3):129–145. doi: 10.1007/BF01806244. [DOI] [PubMed] [Google Scholar]
- Williams M. R., Walker K. J., Turkes A., Blamey R. W., Nicholson R. I. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer. 1986 May;53(5):629–636. doi: 10.1038/bjc.1986.106. [DOI] [PMC free article] [PubMed] [Google Scholar]